Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Boehringer Ingelheim
Covington
Medtronic
Chinese Patent Office
UBS

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 9,446,145

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,446,145
Title:Curcumin-antibody conjugates as anti-cancer agents
Abstract: The invention relates to curcumin derivatives having the formula I: wherein: Z represents: H.sub.3CO A represents --CH.sub.2--CH.sub.2-- or --CH.dbd.CH--; L represents --C(O)--(NH).sub.n1--R--(NH).sub.n2--C(O)--; R represents a saturated or unsaturated, branched or unbranched hydrocarbyl chain having a minimum of 3 carbon atoms in the chain; wherein the maximum number of carbon atoms in the chain is 24; and wherein the carbon atoms of the chain can be replaced by at least one heteroatom, wherein the heteroatoms are independently --O-- or --NH.sub.2--, with the proviso that each heteroatom is separated from each other heteroatom by at least two carbon atoms; n1 and n2 independently represent 0 or 1; and Y represents an antibody that binds specifically to a target antigen of a tumor cell. The invention further relates to methods of method of inhibiting the growth of tumors in a human by administering an effective amount of the curcumin derivative, and to methods of producing the curcumin derivative. ##STR00001##
Inventor(s): Banerjee; Probal (Staten Island, NY), Krishnaswami; Raja (Staten Island, NY)
Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY)
Application Number:13/513,348
Patent Claims:see list of patent claims

Details for Patent 9,446,145

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY) 2029-12-02 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY) 2029-12-02 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY) 2029-12-02 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (New York, NY) 2029-12-02 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Farmers Insurance
US Army
Federal Trade Commission
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.